| 27.13 1.01 (3.87%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.06 | 1-year : | 40.95 |
| Resists | First : | 30.02 | Second : | 35.06 |
| Pivot price | 25.83  |
|||
| Supports | First : | 23.42 | Second : | 19.35 |
| MAs | MA(5) : | 26.09 |
MA(20) : | 26.26 |
| MA(100) : | 30.84 |
MA(250) : | 42.45 |
|
| MACD | MACD : | -0.8 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 84.1 |
D(3) : | 75.7 |
| RSI | RSI(14): 50.5 |
|||
| 52-week | High : | 66.84 | Low : | 19.35 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRCT ] has closed below upper band by 29.0%. Bollinger Bands are 4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.42 - 27.55 | 27.55 - 27.66 |
| Low: | 25.69 - 25.84 | 25.84 - 25.97 |
| Close: | 26.9 - 27.14 | 27.14 - 27.34 |
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Fri, 13 Mar 2026
PROCEPT BioRobotics Corp (PRCT) Trading 4.31% Higher on Mar 13 - GuruFocus
Fri, 13 Mar 2026
TD Cowen Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
Fri, 13 Mar 2026
Mackenzie Financial Corp Raises Stock Position in PROCEPT BioRobotics Corporation $PRCT - MarketBeat
Thu, 12 Mar 2026
PROCEPT BioRobotics® Announces International Launch of the - GlobeNewswire
Thu, 12 Mar 2026
AI-guided BPH treatment robot launches in UK for men on long-term meds - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 56 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 103.2 (%) |
| Shares Short | 7,000 (K) |
| Shares Short P.Month | 6,580 (K) |
| EPS | -1.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.5 |
| Profit Margin | -31.1 % |
| Operating Margin | -40.7 % |
| Return on Assets (ttm) | -12.5 % |
| Return on Equity (ttm) | -24.9 % |
| Qtrly Rev. Growth | 11.8 % |
| Gross Profit (p.s.) | 3.47 |
| Sales Per Share | 5.46 |
| EBITDA (p.s.) | -1.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -15.78 |
| PEG Ratio | 0 |
| Price to Book value | 4.17 |
| Price to Sales | 4.96 |
| Price to Cash Flow | -31.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|